Published in Blood Weekly, January 28th, 2010
"The first aim of this study was to investigate whether 3'-F-18-fluoro-3'-deoxy-L-thymidine (F-18-FLT), a marker of cellular proliferation, is a better tracer for response assessment early after cytotoxic therapy. A second objective of this study was to investigate whether F-18-FDG and F-18-FLT responses were comparable early after mammalian target of rapamycin (mTOR)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.